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Abstract
Background: A large proportion of Syrians have been exposed to potentially traumatic events, multiple losses, and
breakdown of supportive social networks and many of them have sought refuge in host countries where they also
face post-migration living difficulties such as discrimination or integration problems or both. These adversities may
put Syrian refugees at high risk for common mental disorders. In response to this, the World Health Organization
(WHO) developed a trans-diagnostic scalable psychological intervention called Problem Management Plus (PM+) to
reduce psychological distress among populations exposed to adversities. PM+ has been adapted for Syrian refugees
and can be delivered by non-specialist peer lay persons in the community.
Methods: A randomized controlled trial (RCT) will be conducted with 380 Syrian refugees in Turkey. After providing
informed consent, participants with high levels of psychological distress (scoring above 15 on the Kessler-10
Psychological Distress Scale (K10)) and functional impairment (scoring above 16 on the WHO Disability Assessment
Schedule 2.0, or WHODAS 2.0) will be randomly assigned to Group PM+/enhanced care as usual (Group PM+/E-
CAU) (n = 190) or E-CAU (n = 190). Outcome assessments will take place 1 week after the fifth session (post-
assessment), 3 months after the fifth session and 12 months after baseline assessment. The primary outcome is
psychological distress as measured by the Hopkins Symptom Checklist (HSCL-25). Secondary outcomes include
functional impairment, post-traumatic stress symptoms, self-identified problems, and health system and productivity
costs. A process evaluation will be conducted to explore the feasibility, challenges and success of the intervention
with 25 participants, including participants, facilitators, policy makers and mental health professionals.
(Continued on next page)
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Discussion: The treatment manual of the Syrian-Arabic Group PM+ and training materials will be made available
through the WHO once the effectiveness and cost-effectiveness of Group PM+ have been established.
Trial registration: Clinical Trial Registration: ClinicalTrials.gov Identifier NCT03960892. Unique protocol ID: 10/2017.
Prospectively registered on 21 May 2019.
Keywords: Cognitive behavioural therapy, Depression, Anxiety, Post-traumatic stress, Refugee, Mental health, Group
interventions, Task shifting, Trans-diagnostic
Background
The past eight years have resulted in a great increase of Syr-
ian refugees, and Syria has become the principal contributor
to refugees and asylum seekers worldwide [1]. A large pro-
portion of Syrians have sought refuge in neighbouring coun-
tries such as Turkey, Jordan and Lebanon, whereas others
have fled to Europe [2]. Turkey now hosts 3.6 million Syrian
refugees, the largest number of Syrian refugees worldwide
[1]. Syrians residing in Turkey are given the status of “under
temporary protection” and not “refugee status” by the gov-
ernment of the Republic of Turkey. However, for simplicity,
they will be called refugees throughout this article.
Similar to other refugee populations, Syrian refugees may
have been exposed to potentially traumatic events such as
threats to life, injuries, or witnessing deaths during the war
and their flight from conflict [3, 4]. They may face post-
migration difficulties such as unemployment, social isolation
and discrimination after arriving in a host country [3]. Trau-
matic events and post-migration difficulties may make Syrian
refugees more vulnerable to psychological distress and com-
mon mental disorders such as anxiety, depression and post-
traumatic stress disorder (PTSD) [5–10]. If left untreated, psy-
chological distress and mental disorders among refugees may
become more profound and may create a considerable eco-
nomic burden for the community [11]. In Turkey, there are
currently no evidence-based community-based mental health
interventions that Syrian refugees can access and that address
their complex mental health needs. Moreover, Turkey lacks
Arabic-speaking specialized mental health-care professionals
who can deliver such treatments to Syrian refugees. In re-
sponse to this treatment gap, we adapted a World Health
Organization (WHO) psychological intervention called Prob-
lem Management Plus (PM+) for Syrian refugees in Turkey.
PM+ is a brief, scalable, trans-diagnostic psychological
intervention that has been developed as part of the mental
health Gap Action Programme [12]. PM+ addresses symp-
toms of depression, anxiety, PTSD and psychological distress
through cognitive behavioural therapy strategies. Previous
randomized controlled trials (RCTs) have demonstrated the
effectiveness of individually delivered PM+ in Kenya and
Pakistan and of Group PM+ in Pakistan in decreasing de-
pression and anxiety symptoms [13–16]. In Turkey, PM+ is
delivered by trained and supervised non-specialist peer refu-
gees who have a minimum of 12 years of education. Using
peer-Syrian providers as delivery agents overcomes language
issues and has been found to modify the effect on patient
outcomes [17]. In Turkey, Group PM+ is being used. Group
counselling has been found to be as effective as individual
face-to-face sessions [18]. Group sessions also reach more
people at one point in time; another advantage is that pa-
tients benefit from other group members’ experiences and
points of view [19].
The present RCT protocol is part of the larger Syrian Ref-
ugees Mental Health Care Systems (STRENGTHS) (https://
strengths-project.eu/) [20]. STRENGTHS aims to evaluate
the effectiveness and cost-effectiveness of PM+, delivered in
group, individual and e-format by conducting eight RCTs in
countries neighbouring Syria and in European host coun-
tries. STRENGTHS also aims to scale up the delivery and
dissemination of PM+ for Syrian refugees in these countries.
The PM+ group manual has been translated into Arabic and
adapted for Syrian refugees and this work will be presented
elsewhere. The adaptation process was carried out in accord-
ance with the Bernal framework, which consisted of the fol-
lowing steps: (a) literal translation by an Arabic-speaking
WHO translator, (b) free listening and key informant inter-
views with Syrian refugees and mental health professionals
in order to identify key mental health concepts and problems
among Syrian refugees and (c) cognitive testing of the trans-
lated manual [21–23].
Objectives
The main objective of this study is to evaluate the (cost)-
effectiveness of the culturally adapted version of Group
PM+ in adult Syrian refugees with elevated levels of psy-
chological distress in Turkey.
Design and setting
This study is a two-arm, single-blind RCT comparing
Group PM+/E-CAU with E-CAU in 380 study partici-
pants (see the flowchart in Fig. 1). It will be conducted
in collaboration with the partner non-governmental
organization RASASA (Refugee and Asylum Seekers As-
sistance and Solidarity Association) in the Sultanbeyli
District of Istanbul. The Sultanbeyli District is an eco-
nomically deprived area with more than 23,000 Syrians
residing in overcrowded conditions in rented apartment
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blocks with high levels of poverty and unemployment
[24]. RASASA works for the protection of refugees and
provides them with psychosocial support and legal as-
sistance. Methods of recruitment include the distribu-
tion of various advertisements and documents such as
brochures and short movies in addition to social media.
The study protocol has been reported in accordance
with the Standard Protocol Items: Recommendations for
Clinical Interventional Trials (SPIRIT) guidelines (Add-
itional file 1). Figure 1 shows the study flowchart, and
Fig. 2 shows the SPIRIT figure.
Participant recruitment
Participant inclusion criteria
Participants must be adult (18 years or above) Syrians
under temporary protection who are Arabic-speaking
and residing in Turkey. The inclusion criteria include
the following: (1) scoring greater than 16 on the WHO
Disability Assessment Schedule 2.0 (WHODAS 2.0) for
health and disability and (2) scoring greater than 15 on
the Kessler-10 Psychological Distress Scale for psycho-
logical distress [25, 26].
Participant exclusion criteria
Participants will be excluded if they (1) present with
an acute medical condition, (2) have an imminent risk
of suicide, (3) have a severe mental disorder (e.g.,
psychotic disorders or substance dependence) or (4)
show severe cognitive impairment (e.g., severe intel-
lectual disability or dementia). Participants excluded
from the study will be referred for appropriate treat-
ment and support. Participants found to be eligible
will be informed about their eligibility and will be in-
vited to complete a baseline assessment before
randomization (−T1).
n
n n
Fig. 1 Flowchart of the study
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Informed consent
Participants will be invited by the community RASASA
for screening. Participants who attend the screening
interview will be informed about the study and provided
with an informed consent (IC) form which includes the
right to withdraw. Participants will be informed about
the use of their data and the possibility of sharing rele-
vant data with others for research purposes. Biological
specimens will not be collected in this trial. Written or
witnessed oral consent (for illiterate participants) will be
required before completing screening and baseline
assessments.
Sample size and power calculations
The Vrije University (VU) University Medical Centre De-
partment of Epidemiology and Biostatistics carried out the
power calculations for this study. Considering previous
studies with PM+ in Peshawar, Pakistan, and Nairobi,
Kenya, we aim for a conservatively estimated small to
medium Cohen’s d effect size of 0.4 in the PM+ group at
the 3-month follow-up [13, 15]. Power calculations sug-
gest a minimum sample size of 133 participants per group
(power = 0.90, a = 0.05, two-sided). Considering an
expected 30% attrition at the 3-month follow-up, we aim
to include a total number of 380 participants (190 in the
Group PM+/E-CAU group and 190 in the E-CAU group).
Randomization
After baseline assessment, participants will be randomly
assigned on a 1:1 basis to either Group PM+/E-CAU (n
= 190) or E-CAU (n = 190) (T0). Randomization using
computerized software will be carried out by an inde-
pendent researcher who is not involved in the interven-
tion delivery, clinical supervision, assessments or other
aspects of the study.
There is a chance that participants of the study will be
recruited from the same household, creating a risk for
contamination (if family members were to be allocated
to receive different treatments, namely either Group
PM+ or E-CAU). To limit the likelihood of contamin-
ation, participants from the same household will be
assigned to the same intervention arm.
Group PM+
PM+ is a brief, trans-diagnostic psychological interven-
tion based on cognitive behavioural therapy techniques
TIMEPOINT Enrolment (-t1 )
Allocation
(0)
Intervention (t1 ) Post-assessment (t2 )
3 Month Follow-up
Assessment (t3)
12 Month
Follow-up
Assessment (t4)
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Group PM+ & ECAU X X
ECAU X X
ASSESSMENTS:
WHODAS 2.0 X X X X
K10 X
HSCL-25 X X X X
PCL-5 X X X X
PSYCHOLOPS X X X X
Trauma
Experiences
X X
PMLD X X X
CSRI X X X X
Access to Health
Care
X X X X
Fidelity Checklist X
STUDY PERIOD
Post-allocation
Fig. 2 Overview of the study measures
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and developed by the WHO [12, 27]. It consists of five
sessions delivered in five consecutive weeks and aims to
reduce symptoms of depression, anxiety, PTSD and re-
lated conditions. Groups are separated by gender, and
gender-matched facilitators will lead groups consisting
of six to eight participants (T1). Sessions include
evidence-based strategies of stress management,
problem-solving, behavioural activation and strengthen-
ing social support. PM+ is designed to be delivered by
non-specialist helpers who receive an 8-day training in
PM+. These Arabic-speaking non-specialist helpers, who
are called facilitators, are supervised by psychologists
and psychiatrists who have participated in the PM+
training-of-trainers program. Supervision consists of
weekly, face-to-face group supervision and individual
supervision when needed.
Enhanced usual care
Syrians in Turkey have free access to mental health ser-
vices in public hospitals and migrant health centres [28].
However, owing to numerous barriers such as lack of
knowledge of available mental health services or (self)-
stigma, the use of mental health services is low among
Syrian refugees [29, 30]. Usual care will be enhanced by
providing study participants with a leaflet on publicly
available mental health services in the area where they
live. Implementing Group PM+ or E-CAU will not re-
quire alteration to usual care pathways (including use of
any medication) and these will continue for both trial
arms.
Outcome measures
All instruments will be administered by trained research
staff blind to the allocation status of the participants at
post-assessment (1 week after the fifth PM+ session)
(T1), 3 months after the baseline (T2) and 12months
after baseline (T3).
Primary outcome measure
The primary outcome measure of this study is the Hop-
kins Symptom Checklist (HSCL-25). This assesses anx-
iety and depression symptom levels at 3-month follow-
up assessment [31]. It has 25 items, namely two sub-
scales for depression (13 items) and anxiety symptoms
(10 items) and two items related to somatic symptoms.
These items are scored on a 4-point Likert scale.
Secondary outcome measures
The secondary outcome measures are (1) the PTSD
Checklist for DSM-5 (PCL-5) to assess the severity of
post-traumatic stress reactions, (2) Psychological Out-
comes Profiles (PSYCHLOPS) to assess self-identified
problems, (3) the Client Service Receipt Inventory
(CSRI) to assess health service utilization and
productivity impacts, and (4) WHODAS, which is also
part of the screening and which assesses functional dis-
ability [32, 33]. In addition, perceived access to health
services will be measured (see Fig. 2). The PCL-5 has 20
items scored on a 0–4 scale, adding up to a total severity
score of 80, and higher scores indicate higher levels of
symptomatology. PSYCHLOPS consists of four ques-
tions on three domains: problems (two questions), func-
tion (one question) and wellbeing (one question).
Problem and function questions are asked in the form of
free texts, and the responses are scored on an ordinal 6-
point scale, producing a maximum score of 20. The
CSRI includes questions about resource use for health
and social care services, informal care, and productivity
as a result of functionality in people with mental disor-
ders. The CSRI has been adapted for Syrians in Turkey
to match Turkish health-care services that are available
to Syrians. Relevant unit costs will be attached to service
utilisation to estimate changes in use of health services
and health-care costs, while Turkish minimum wage
rates will be used to conservatively estimate changes in
costs associated with both informal family care and lost
productivity by the patient from work.
Other measures
A self-constructed questionnaire will be used to as-
sess lifetime trauma exposure. This questionnaire in-
cludes items from the Harvard Trauma
Questionnaire (HTQ) and the Post-traumatic Diag-
nostic Scale (PDS) and asks questions on specific
traumatic experiences of Syrian refugees. It has 28
items scored as 0 (no) or 1 (yes), and the total score
ranges from 0 to 28 [34, 35].
The Post-Migration Living Difficulties Checklist
(PMLDC) will be used to assess post-migration stressors.
The PMLDC has 17 items scored on a 5-point scale,
ranging from 0 to 4 (0 = not a problem and 4 = very ser-
ious problem) (range 0–68). Items scored at least 2 (a
moderately serious problem) are considered positive re-
sponses [36, 37].
If the validated Arabic version of the included mea-
sures is available, they will be selected and tested
through cognitive interviews with Arabic-speaking adult
Syrians. If the validated Arabic version of the measures
is not available, these measures will be translated and
back-translated in accordance with the WHO guidelines
[38].
All randomly assigned participants, including those
who discontinue, will be invited to all outcome assess-
ments. In case participants do not attend a scheduled
outcome assessment, they will be called a maximum of
five times (on different days) to schedule a new
appointment.
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Process evaluation
We will explore the feasibility, challenges and success of
the intervention through semi-structured interviews with
facilitators, PM+ participants, policy makers and health
professionals. From each category, five participants will
be included. Interviews will take between 30 and 60 min
and will start after ICs are obtained from the partici-
pants. Moreover, PM+ dose (i.e., number of sessions
completed), treatment fidelity and quality will be
assessed. Participant adherence to the intervention will
be monitored by recording their attendance to sessions.
Attendance to fewer than three sessions will be counted
as dropout. Facilitators will be allowed to deliver PM+
sessions with participants after training and a compe-
tency assessment. Facilitators receive weekly supervision
to ensure that intervention content is adhered to. More-
over, facilitators will be asked to complete a structured
checklist on the Group PM+ components immediately
after completion of each session. Trained staff members
will be present during 10% of the PM+ sessions and will
score treatment fidelity by using a checklist of the re-
quired PM+ elements [39].
We will promote participant retention by sending text
messages to participants to remind them of their appoint-
ments. We will also regularly update phone numbers and
other contact information of participants. Moreover, we
offer weekend and evening hours for group sessions and
outcome assessments and provide a child-friendly place
for children. This may facilitate treatment access and may
have a positive impact on participant retention. Partici-
pants who come to group sessions and outcome assess-
ments will be reimbursed for travel.
Data management
All data will be handled confidentially by the data moni-
toring committee, which consists of two researchers from
Istanbul Sehir University (ISU). Quantitative data will be
collected either through pen-and-paper format or through
tablets. The quantitative data and the identifying key (a list
connecting names to numbers) will be kept in a separate
and secure locked location at the Trauma Research Lab at
ISU. The data will be entered into a data-analytic com-
puter program without the identifying key.
Qualitative interviews will be saved separately from
the participants’ identifiers and will be transcribed and
safely stored at the Trauma Research Lab at ISU. There
will be no audio data since the Immigration Authority of
Turkey does not give permission to make audio record-
ings in research studies with Syrian refugees (see ‘Ethics
approval and consent to participate’ section).
Statistical methods
Descriptive analyses will be carried out in Statistical
Package for the Social Sciences (SPSS) and Hierarchical
Linear Modelling (HLM) analyses in Stata version 11.2.
Across all analyses, two-tailed tests will be reported with
a P value of less than 0.05. To estimate the effectiveness
and cost-effectiveness of Group PM+, the following data
analysis methods will be conducted. First, to examine
whether there are differences between conditions, t tests
(continuous variables) or chi-squared test (categorical
variables) will be conducted at baseline to compare the
two intervention arms (i.e., Group PM+/E-TAU vs. E-
TUA) for normally distributed data; Mann–Whitney
tests will be conducted for continuous non-normally dis-
tributed data.
Intention-to-treat (ITT) analyses, including all ran-
domly assigned participants (N = 380) and treatment
completers’ (per protocol) analyses, will be conducted.
The primary outcomes of the trial will be the ITT ana-
lyses. A linear mixed model will be used for the primary
endpoint analysis to estimate the intervention effect,
which will have intervention as fixed effects, baseline
measurement of primary endpoint as covariate, and par-
ticipants as random effects.
The mean difference between the two treatment arms
at each visit/time together with its 95% confidence inter-
val will be derived from the mixed model. A covariate-
adjusted mixed model for the primary endpoint will be
performed by adding pre-specified covariates at baseline
(gender, age, education, traumatic experiences, post-
migration difficulties, etc.) into the above model. Missing
data will be treated as missing at random. No imputa-
tions of missing values will be made, as multilevel
models can deal with missing data [40]. Qualitative data
from the process evaluation will be analysed thematically
in accordance with the framework approach [41]. Inter-
view transcripts will be coded by using Nvivo version 11
[42].
Economic analyses
The economic analysis will be conducted from both a
health sytem perspective, and from a broader perspctive
including productivity impacts in order to determine the
difference in costs and outcomes in Group PM+/E-
CAU, compared with E-CAU. Costs will be compared
between arms using a regression model, controlling for
baseline, and with bootstrapped confidence intervals
using 10,000 resamples. Incremental cost-effectiveness
ratios (ICERs) will be calculated comparing changes in
mean costs and primary outcomes from both payer and
societal perspectives between the two groups. Non-
parametric bootstrapping analyses, using 10,000 resamples,
will be performed to account for uncertainty and derive
95% confidence intervals around ICERs in order to generate
cost-effectiveness planes. Cost-effectiveness acceptability
curves will be plotted to present the probability that the
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PM+/E-CAU intervention is cost-effective at various
willingness-to-pay threshold levels.
Ethical considerations
The study protocol received approval from the ISU Re-
search Ethics Committee on 12 April 2017 (Protocol ID:
12/2017) and the Immigration Authority of the Republic
of Turkey to conduct the study on 29 March 2017. The
STRENGTHS Safety Board (SB) will ensure that the trial
and data collection are conducted in accordance with
the principles of the Declaration of Helsinki (64th WMA
General Assembly, Fortaleza, Brazil, October 2013). It
will be in accordance with the International Conference
on Harmonisation, WHO Good Clinical Practice stan-
dards, and the Medical Research Involving Human Sub-
jects Act (WMO). There is no anticipated harm or
compensation for trial participation. Cases of clinical
worsening will be referred to tertiary care.
Trial management
The trial management committee consists of the site
principal investigator (PI) and research coordinators,
who are responsible for monitoring of all study proce-
dures. Overall trial management is provided by the inter-
national PI and senior research and intervention staff,
who hold monthly telephone conferences and meet an-
nually in a face-to-face consortium meeting. The
STRENGTHS SB will monitor all ethical, legal and soci-
etal issues that arise within the STRENGTHS project. In
addition, the safety, rights and wellbeing of study partici-
pants and research staff will be reviewed, and interim
analyses will be considered in case safety issues are (sus-
pected to be) violated. Relevant issues will be discussed
periodically (on a 6-month basis); the SB will request
that additional meetings be held if issues arise in the
interim.
Moreover, any amendments to the protocol will be
made after a favourable opinion of the consortium and
the ISU Research Ethics Committee. The coordinator of
the project will then notify the funder and will update
the protocol in the clinical trial registry. Any deviations
from the protocol will be fully documented by using a
breach report form.
Adverse event monitoring
All adverse events (AEs) and serious adverse events
(SAEs) will be recorded through the web-based software,
Castor Electronic Data Capture. SAEs will be reported
to the ISU Research Ethics Committee within 15 days.
SAEs that result in death or are life-threatening will be
reported within 48 hours. All AEs will be followed until
they have abated or until a stable situation has been
reached.
Discussion
This study reports the protocol of an RCT that evaluates
the effectiveness and cost-effectiveness of the culturally
adapted version of Group PM+ among adult Syrians res-
iding in Turkey. PM+ is a five-session-long, trans-
diagnostic psychological intervention developed by the
WHO and aims to decrease symptoms of psychological
distress (depression, anxiety and PTSD) and to improve
psychosocial functioning.
This study builds on prior research that has demon-
strated the effectiveness of PM+ in different settings in
decreasing depression and anxiety symptoms [13, 15,
16]. However, PM+ has not been adapted for Syrian ref-
ugees who migrated to Europe and the Middle East after
experiencing adversities in Syria, during and after migra-
tion. We hypothesise that training Arabic speakers in
Group PM+ and providing peer-to-peer Group PM+ to
refugees may be useful in overcoming the mental health
treatment gap we are seeing in this population group. If
proven to be effective, the adapted Group PM+ version
will be disseminated by the WHO and recommended for
scaling up.
Trial status
The trial was registered at ClinicalTrials.gov on 21 May
2019 (ClinicalTrials.gov Identifier: NCT03960892, proto-
col version 4.2/201903). Recruitment of participants
began on 3 August 2019 and we are planning to finish it
in June 2020.
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